Quantification of Mycophenolic Acid in Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Publisher: Humana Press Country of Publication: United States NLM ID: 9214969 Publication Model: Print Cited Medium: Internet ISSN: 1940-6029 (Electronic) Linking ISSN: 10643745 NLM ISO Abbreviation: Methods Mol Biol Subsets: MEDLINE

Publication: Totowa, NJ : Humana Press
Original Publication: Clifton, N.J. : Humana Press,

Mycophenolic Acid* ; Tandem Mass Spectrometry*/methods; Humans ; Chromatography, High Pressure Liquid/methods ; Chromatography, Liquid/methods ; Glucuronides ; Reproducibility of Results

Mycophenolate mofetil (MMF) and sodium mycophenolate are commonly prescribed immunosuppressive drugs for patients who have undergone solid organ transplant. Therapeutic drug monitoring (TDM) of these drugs is performed by assessing mycophenolic acid (MPA) in plasma. Due to the large inter-individual variability and narrow therapeutic range, the precise determination of systemic MPA concentration carries great clinical significance. We present a rapid, sensitive, specific, and robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantitation of MPA in plasma. A Waters Xevo TQ-S Micro mass spectrometer coupled to a Water's Acquity liquid chromatography system was used in positive electrospray ionization (ESI) mode. MPA quantitation was achieved using multiple reaction monitoring (MRM). Mycophenolic acid carboxybutoxy ether (MPAC) was employed as an internal standard. The method is linear from 0.25 to 40.00 mg/L, has intra-assay (N = 24) imprecision of 2.7% at 1.57 mg/L and 3.9% at 4.61 mg/L and inter-assay (N = 20 days) imprecision of 4.0% at 1.62 mg/L and 5.6% at 4.68 mg/L.
(© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Van Gelder T, Van Schaik RH, Hesselink DA (2014) Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol 10(12):725–731. (PMID: 10.1038/nrneph.2014.17225247332)
Klepacki J, Klawitter J, Bendrick-Peart J, Schniedewind B, Heischmann S, Shokati T, Christians U, Klawitter J (2012) A high-throughput U-HPLC–MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. J Chromatogr B 883:113–119. (PMID: 10.1016/j.jchromb.2011.07.021)
Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2(1):184–191. (PMID: 10.2215/CJN.0286080617699403)
Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E (2000) Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46(3):365–372. (PMID: 10.1093/clinchem/46.3.36510702523)
Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, Oellerich M, German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant R (2002) Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24(3):390–399. (PMID: 10.1097/00007691-200206000-0001112021631)
Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25(1):1–16. (PMID: 10.1097/00007691-200302000-0000112548138)
de Winter BCM, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RAA (2009) Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 36:541–564. (PMID: 10.1007/s10928-009-9136-6199045842784070)
Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34(6):429–455. (PMID: 10.2165/00003088-199834060-000029646007)
Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE (2014) PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics 24(1):73. (PMID: 10.1097/FPC.0000000000000010242202074091813)
Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation. Clin Pharmacokinet 41(10):751–790. (PMID: 10.2165/00003088-200241100-0000512162761)
Spector R, Park GD, Johnson GF, Vesell ES (1988) Therapeutic drug monitoring. Clin Pharmacol Ther 43(4):345–353. (PMID: 10.1038/clpt.1988.423281773)
Budde K, Glander P (2008) Pharmacokinetic principles of immunosuppressive drugs. Ann Transplant 13(3):5–10. (PMID: 18806727)
Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P (2004) Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 26(6):609–619. (PMID: 10.1097/00007691-200412000-0000515570184)
Prémaud A, Rousseau A, Picard N, Marquet P (2006) Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography–tandem mass spectrometry. Ther Drug Monit 28(2):274–277. (PMID: 10.1097/01.ftd.0000197092.84935.ef16628144)
Merrigan SD, Kish-Trier E, Seegmiller JC, Johnson-Davis KL (2017) LC–MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clin Mass Spectrom 3:41–48. (PMID: 10.1016/j.clinms.2017.07.001)

Keywords: Liquid chromatography; Mass spectrometry; Mycophenolic acid; Plasma; Quantification

HU9DX48N0T (Mycophenolic Acid)
0 (Glucuronides)

Date Created: 20231130 Date Completed: 20231204 Latest Revision: 20231204

20240514

10.1007/978-1-0716-3541-4_30

38036834